Host immunity recognizes and eliminates most early tumor cells, yet immunological
checkpoints, exemplified by CTLA-4, PD-1, and PD-L1, pose a significant obstacle to …

Objective To formulate clinical practice guidelines for the endocrine treatment of
hypothalamic–pituitary and growth disorders in survivors of childhood cancer. Participants …

Hypophysitis that develops in cancer patients treated with monoclonal antibodies blocking
cytotoxic T-lymphocyte–associated protein 4 (CTLA-4; an inhibitory molecule classically …

Cancer survival rates are generally increasing in the United States. These trends have been
partially attributed to improvement in therapeutic strategies. Cancer immunotherapy is an …

Immune checkpoint inhibitors have recently become a cornerstone for the treatment of
different advanced cancers. These drugs, represented mainly by monoclonal antibodies anti …

A complex relationship exists between thyroid and liver in health and disease. Liver plays an
essential physiological role in thyroid hormone activation and inactivation, transport, and …

Introduction: Immune checkpoint inhibitors (ICI) are associated with a wide spectrum of
neurologic immune-related adverse events (irAEs) including meningo-encephalitis …

Background The aim of this meta-analysis was to assess the risks and incidence of
nephrotoxicity and electrolyte abnormalities in patients receiving programmed cell death …

The management of cancer patients has changed due to the considerably more frequent
use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side …

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1
(PD-1) are inhibitory checkpoints that are commonly seen on activated T cells and have …